

Supporting Information

Toluene Derivatives as Simple Coupling Precursors for Cascade Palladium-Catalyzed Oxidative C-H bond Acylation of Acetanilides

Yinuo Wu,^a Pui Ying Choy,^a Fei Mao^b and Fuk Yee Kwong^{a*}

^a*State Key Laboratory of Chirosciences and Department of Applied Biology and
Chemical Technology, The Hong Kong Polytechnic University, Hong Kong;*

^b*School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006,
China*

E-mail: fuk-yee.kwong@polyu.edu.hk




Table of Contents

1. General considerations	2
2. Preparation of substituted acetanilide substrates.....	3
3. General procedures for reaction condition screenings and coupling reactions	3
4. Characterization data of coupling products.....	6
5. ¹ H and ¹³ C NMR and HRMS spectra	20
6. References	80

1. General considerations

Unless otherwise noted, all reagents were purchased from commercial suppliers and used without purification. All the reactions were performed in RotaFlo[®] (England) resealable screw-cap Schlenk flask (approx. 20 mL volume) in the presence of Teflon coated magnetic stirrer bar (4 mm × 10 mm). Dichloroethane (DCE) was distilled under calcium hydride under reduced pressure. Dioxane and toluene were distilled from sodium under nitrogen. Acetonitrile was distilled from calcium hydride under nitrogen prior to use. The concentration of *tert*-butyl hydroperoxide (TBHP) was determined by means of iodometric method.^[1] Thin layer chromatography was performed on Merck precoated silica gel 60 F254 plates. Silica gel (Merck, 70-230 and 230-400 mesh) was used for column chromatography. ¹H NMR spectra were recorded on a Bruker (400 MHz) spectrometer. Spectra were referenced internally to the residual proton resonance in CDCl₃ (δ 7.26 ppm), or with tetramethylsilane (TMS, δ 0.00 ppm) as the internal standard. Chemical shifts (δ) were reported as part per million (ppm) in δ scale downfield from TMS. ¹³C NMR spectra were referenced to CDCl₃ (δ 77.0 ppm, the middle peak). Coupling constants (*J*) were reported in Hertz (Hz). High-resolution mass spectra (HRMS) were obtained on a Bruker APEX 47e FT-ICR mass spectrometer (ESIMS). GC-MS analysis was conducted on a HP 5973 GCD system using a HP5MS column (30 m × 0.25 mm). The products described in GC yield were accorded to the authentic samples/dodecane calibration standard from HP 6890 GC-FID system. Compounds described in the literatures were characterized by comparison of their ¹H, and/or ¹³C NMR spectra to the previously reported data.

2. Preparation of substituted acetanilide substrates

All the substituted acetanilides in Table 3 were prepared from their corresponding precursors with Ac₂O in CH₂Cl₂ according to the literature method without modifications.^[2]

N-phenylbenzamide, *N*-phenylpivalamide and *N*-phenylisobutyramide in Scheme 2 were prepared from phenylamine with their corresponding acyl chlorides in pyridine according to the literature method without modifications.^[3]

3. General procedures for reaction condition screenings and coupling reactions

General procedures for screening: Acetanilide (0.135 g, 1.0 mmol) and metal complex (10 mol% or as indicated in Table 1) were loaded into a Schlenk tube equipped with a Teflon-coated magnetic stir bar under air. 4-Chlorotoluene (2.0 mL) was added into the tube. The solution was stirred for about 1 to 2 minutes until all solid dissolved. TBHP (12.0 mmol or as indicated in Table 1) were loaded into the tube. The tube was stirred at room temperature for ~5 minutes and then placed into a preheated oil bath (40-120 °C) for 24 hours. After completion of reaction, the reaction tube was allowed to cool to room temperature. Ethyl acetate (~10 mL), dodecane (227 µL, internal standard) and water (~3 ml) were added. The organic layer was subjected to GC analysis. The GC yield obtained was previously calibrated by authentic sample/dodecane calibration curve.

General procedure for C-H bond coupling of acetanilides and substituted toluene:

Substituted acetanilide (1.0 mmol) and Pd(OAc)₂ (22.4 mg, 0.10 mmol) were loaded into a Schlenk tube equipped with a Teflon-coated magnetic stir bar under air. Substituted toluene (2.0 mL) was added into the tube (Substituted toluene in solid form was added in 80 *equiv.*). TBHP (12.0 mmol) were loaded into the tube. The tube was stirred at room temperature for ~5 minutes and then placed into a preheated oil bath at 80 °C for 24 hours. After completion of reaction as judged by GC analysis, the reaction tube was allowed to cool to room temperature and quenched with saturated K₂CO₃. The organic layer was separated and the aqueous layer was washed with EtOAc. The filtrate was concentrated under reduced pressure. The crude products were purified by flash column chromatography on silica gel (230-400 mesh) to afford the desired oxidatively coupled product.

Table 1 Screening of reaction conditions^a


Reaction scheme: Acetanilide (**1a**) + 4-chlorotoluene (**2l**) $\xrightarrow[oxidant, temp.]{10\ mol\% catalyst}$ 4-(4-chlorobenzoyl)acetanilide (**3al**)

entry	catalyst	oxidant (equiv.)	temp. /°C	%yield ^[b]
1	Pd(OAc) ₂	TBHP (6)	100	15
2	PdCl ₂	TBHP (6)	100	6
3	Pd(MeCN) ₂ Cl ₂	TBHP (6)	100	9
4	Pd(TFA) ₂	TBHP (6)	100	15
5	Ni(acac) ₂	TBHP (6)	100	0
6	Rh(PPh ₃) ₃ Cl	TBHP (6)	100	0
7	Pd(OAc) ₂	air	100	0
8	Pd(OAc) ₂	K ₂ S ₂ O ₈ (6)	100	5
9	Pd(OAc) ₂	PhI(OAc) ₂ (6)	100	0
10	Pd(OAc) ₂	(<i>t</i> -BuO) ₂ (6)	100	6
11	Pd(OAc) ₂	TBHP (8)	100	39
12	Pd(OAc) ₂	TBHP (10)	100	76
13	Pd(OAc) ₂	TBHP (12)	100	88
14	Pd(OAc) ₂	TBHP (16)	100	89
15	Pd(OAc)₂	TBHP (12)	80	94 (90)
16	Pd(OAc) ₂	TBHP (12)	60	66
17	Pd(OAc) ₂	TBHP (12)	40	58
18 ^[c]	Pd(OAc) ₂	TBHP (12)	80	11
19 ^[d]	Pd(OAc) ₂	TBHP (12)	80	0
20 ^[e]	Pd(OAc) ₂	TBHP (12)	80	6
21 ^[f]	Pd(OAc) ₂	TBHP (12)	80	60

^a Reaction conditions: Acetanilide **1a** (1.0 mmol), catalyst (10 mol%), oxidant (as indicated), 4-chlorotoluene **2l** (2 mL) were stirred at indicated reaction temperature for 24 h under air. ^bCalibrated GC yields were reported using dodecane as the internal standard. Isolated yield in parenthesis. ^cDCE as solvent (**2l**, 10 equiv.). ^dDioxane as solvent (**2l**, 10 equiv.). ^eMeCN as solvent (**2l**, 10 equiv.). ^f5 mol% Pd(OAc)₂ was used.


4. Characterization data of coupling products

N-(2-(1-Naphthoyl)phenyl)acetamide (Table 2, product 3ab)^[4]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.49 (s, 1H), 8.69 (d, J = 8.5 Hz, 1H), 7.91 (dd, J = 7.5, 1.5 Hz, 1H), 7.86-7.79 (m, 2H), 7.50-7.43 (m, 2H), 7.43-7.38 (m, 3H), 7.32 (dd, J = 8.0, 1.5 Hz, 1H), 6.92-6.79 (m, 1H), 2.20 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 202.16, 169.66, 141.54, 137.01, 135.39, 134.82, 133.63, 131.21, 130.63, 128.55, 127.41, 127.18, 126.62, 125.31, 124.43, 123.24, 122.19, 120.87, 25.56.

N-(2-(2-Naphthoyl)phenyl)acetamide (Table 2, product 3ac)^[4]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.79 (s, 1H), 8.66 (d, J = 8.3 Hz, 1H), 8.18 (s, 1H), 7.94 (dd, J = 12.3, 8.7 Hz, 3H), 7.84 (dd, J = 8.5, 1.6 Hz, 1H), 7.68-7.54 (m, 4H), 7.15-7.07 (m, 1H), 2.24 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.38, 172.01, 140.29, 135.94, 135.23, 134.20, 133.49, 132.45, 131.84, 129.55, 128.64, 128.31, 127.83, 127.05, 126.77, 125.42, 122.28, 121.78, 25.25.

***N*-(2-Benzoylphenyl)acetamide (Table 2, product 3ad)**^[5]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.81 (s, 1H), 8.60 (d, J = 8.2 Hz, 1H), 7.71-7.67 (m, 2H), 7.56 (dd, J = 15.8, 7.8 Hz, 3H), 7.48 (t, J = 7.6 Hz, 2H), 7.35-7.33 (m, 1H), 7.08 (s, 1H), 2.21 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.75, 169.44, 140.35, 134.28, 133.53, 132.57, 129.92, 128.36, 126.97, 122.18, 121.60, 25.23.

***N*-(2-(2-Methylbenzoyl)phenyl)acetamide (Table 2, product 3ae)**^[4]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.56 (s, 1H), 8.75 (d, J = 8.5 Hz, 1H), 7.56 (dd, J = 11.4, 4.3 Hz, 1H), 7.39 (dd, J = 9.4, 2.6 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.25-7.22 (m, 1H), 7.00 (t, J = 7.6 Hz, 1H), 2.29 (s, 3H), 2.28 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 202.92, 169.57, 141.54, 139.29, 135.90, 135.32, 134.52, 130.94, 130.25, 127.87, 125.38, 122.46, 122.17, 120.74, 25.55, 19.73.

***N*-(2-(2-Methoxybenzoyl)phenyl)acetamide (Table 2, product 3af)^[6]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.61 (s, 1H), 8.75 (d, J = 8.5 Hz, 1H), 7.58-7.53 (m, 1H), 7.52-7.44 (m, 2H), 7.32-7.28 (m, 1H), 7.06 (td, J = 7.5, 0.7 Hz, 1H), 7.04-6.97 (m, 2H), 3.77 (d, J = 3.4 Hz, 3H), 2.26 (d, J = 15.3 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 200.62, 169.64, 156.81, 141.29, 135.09, 134.55, 131.99, 129.09, 128.50, 126.95, 122.58, 120.49, 120.47, 111.44, 55.64, 25.55.

***N*-(2-(4-Methoxybenzoyl)phenyl)acetamide (Table 2, product 3ag)^[4]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.44 (s, 1H), 8.47 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 8.8 Hz, 2H), 7.45 (dd, J = 10.1, 3.9 Hz, 2H), 7.01 (dd, J = 11.3, 3.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 3.80 (s, 3H), 2.11 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.89, 169.04, 163.45, 139.80, 133.51, 132.72, 132.61, 130.88, 124.27, 122.07, 121.72, 113.64, 55.52, 25.14.

***N*-(2-(3,5-Dimethoxybenzoyl)phenyl)acetamide (Table 2, product 3ah)^[12]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.69 (s, 1H), 8.53 (d, J = 8.3 Hz, 1H), 7.58-7.38 (m, 2H), 7.01 (t, J = 7.6 Hz, 1H), 6.73 (d, J = 2.2 Hz, 2H), 6.60 (t, J = 2.2 Hz, 1H), 3.74 (s, 6H), 2.16 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.40, 169.30, 160.55, 140.45, 140.38, 134.37, 133.51, 122.12, 121.54, 107.65, 104.81, 55.62, 25.26.

***N*-(2-(2-Fluorobenzoyl)phenyl)acetamide (Table 2, product 3ai)^[4]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.36 (s, 1H), 8.75 (d, J = 8.5 Hz, 1H), 7.62-7.57 (m, 1H), 7.54 (dd, J = 6.7, 1.4 Hz, 1H), 7.52-7.48 (m, 1H), 7.45 (d, J = 7.0 Hz, 1H), 7.31 – 7.25 (m, 1H), 7.20 (d, J = 9.4 Hz, 1H), 7.09-7.03 (m, 1H), 2.28 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.09, 169.48, 158.4, 141.32, 135.57, 134.16, 133.04 (d, J_{CF} = 8.3 Hz), 130.19 (d, J_{CF} = 2.3 Hz), 127.61 (d, J_{CF} = 16.8 Hz), 124.28 (d, J_{CF} = 3.5 Hz), 122.27, 120.79, 116.37 (d, J_{CF} = 21.4 Hz), 25.52.

***N*-(2-(4-Fluorobenzoyl)phenyl)acetamide (Table 2, product 3aj)**^[4]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.65 (s, 1H), 8.61 (d, J = 8.4 Hz, 1H), 7.82-7.74 (m, 2H), 7.64-7.49 (m, 2H), 7.19 (t, J = 8.6 Hz, 2H), 7.11 (s, 1H), 2.24 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.81, 169.09, 166.53, 164.00, 140.06, 134.56 (d, J_{CF} = 3.1 Hz), 132.90, 132.49 (d, J_{CF} = 9.2 Hz), 127.57 (d, J_{CF} = 155.5 Hz), 123.30, 121.88 (d, J_{CF} = 43.1 Hz), 115.43 (d, J_{CF} = 22.0 Hz), 25.07.

***N*-(2-(2-Chlorobenzoyl)phenyl)acetamide (Table 2, product 3ak)**^[4]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.56 (s, 1H), 8.86-8.74 (m, 1H), 7.60 (s, 1H), 7.51-7.45 (m, 2H), 7.38 (ddd, J = 5.5, 3.3, 1.7 Hz, 2H), 7.33 (dd, J = 7.5, 1.3 Hz, 1H), 7.06-6.99 (m, 1H), 2.31 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.27, 169.65, 141.92, 138.74, 135.95, 134.60, 131.20, 130.94, 130.14, 128.65, 126.75, 122.28, 121.27, 120.64, 25.63.

***N*-(2-(4-Chlorobenzoyl)phenyl)acetamide (Table 2, product 3aI)^[4]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.70 (s, 1H), 8.62 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.59 (t, J = 7.9 Hz, 1H), 7.49 (dd, J = 13.5, 8.1 Hz, 3H), 7.10 (t, J = 7.6 Hz, 1H), 2.23 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 195.92, 168.10, 138.62, 137.81, 135.07, 133.14, 131.21, 130.29, 127.94, 126.01, 123.24, 122.25, 23.99.

***N*-(2-(2-Bromobenzoyl)phenyl)acetamide (Table 2, product 3aM)^[4]**



Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.54 (s, 1H), 8.80 (d, J = 8.5 Hz, 1H), 7.65 (dd, J = 7.9, 0.9 Hz, 1H), 7.57 (dd, J = 11.4, 4.2 Hz, 1H), 7.39-7.32 (m, 3H), 7.30-7.28 (m, 1H), 7.03-6.98 (m, 1H), 2.29 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 199.88, 169.63, 142.03, 140.83, 135.94, 134.68, 133.23, 131.23, 128.56, 127.28, 122.27, 120.98, 120.64, 119.25, 25.62.


***N*-(2-(4-Acetylbenzoyl)phenyl)acetamide (Table 2, product 3an)**



3an

Hexane: EtOAc = 1:4, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 7.95-7.93 (d, J = 8.0 Hz, 1H), 7.82-7.80 (d, J = 8.0 Hz, 1H), 7.76-7.74 (d, J = 8.0 Hz, 1H), 7.39-7.37 (d, J = 8.0 Hz, 1H), 7.25-7.24 (m, 1H), 7.22-7.17 (s, 1H), 2.47 (s, 3H); 2.44 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.64, 197.45, 171.20, 143.99, 140.66, 139.78, 133.58, 130.40, 129.84, 125.91, 122.20, 121.62, 27.00, 24.85. HRMS(H^+): calcd. for $\text{C}_{17}\text{H}_{16}\text{NO}_3$: 282.3218, found 282.3210.


***N*-(2-(benzo[d]oxazole-2-carbonyl)phenyl)acetamide (Table 2, product 3ao)**



3ao


Hexane: EtOAc = 1:2.5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 8.56 (s, 1H), 8.42 (s, 1H), 7.87-7.85 (d, J = 8.0 Hz, 1H), 7.75-7.63 (m, 1H), 7.56-7.52 (t, J = 11.4, 4.2 Hz, 1H), 7.43 – 7.41 (m, 2H), 7.39-7.26 (m, 1H), 2.27 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 179.91, 171.31, 169.39, 160.39, 149.33, 137.38, 132.12, 130.69, 125.91, 124.10, 119.54, 116.59, 114.20, 107.43, 104.17, 24.85. HRMS(H^+): calcd. for $\text{C}_{16}\text{H}_{12}\text{N}_2\text{O}_3$: 281.2832, found 282.2829.

***N*-(5-Chloro-2-(4-chlorobenzoyl)phenyl)acetamide (Table 3, product 3bl)^[12]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.87 (s, 1H), 8.75 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 8.5 Hz, 2H), 7.50-7.44 (m, 3H), 7.07 (dd, J = 8.5, 2.0 Hz, 1H), 2.24 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.62, 169.28, 141.63, 141.03, 139.23, 136.65, 134.29, 131.15, 128.83, 122.36, 121.42, 120.79, 25.31.

***N*-(4-Chloro-2-(4-chlorobenzoyl)phenyl)acetamide (Table 3, product 3cl)^[9]**




Hexane: EtOAc = 1:3, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.52 (s, 1H), 8.60 (d, J = 9.0 Hz, 1H), 7.67 (d, J = 8.5 Hz, 2H), 7.56-7.45 (m, 4H), 2.23 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 195.92, 167.80, 139.06, 137.79, 135.35, 133.14, 131.21, 130.29, 127.94, 126.30, 123.31, 122.25, 24.19.

***N*-(4-Bromo-2-(4-chlorobenzoyl)phenyl)acetamide (Table 3, product 3dl)^[10]**




Hexane: EtOAc = 1:3, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.52 (s, 1H), 8.54 (d, J = 9.0 Hz, 1H), 7.69-7.63 (m, 3H), 7.61 (d, J = 2.3 Hz, 1H), 7.53-7.49 (m, 2H), 2.22 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 196.94, 169.13, 139.65, 139.29, 137.06, 136.08, 135.12, 131.32, 128.97, 124.68, 123.51, 114.68, 25.24.

***N*-(2-(4-Chlorobenzoyl)-6-methylphenyl)acetamide (Table 3, product 3el)^[12]**




Hexane: EtOAc = 1:3, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 7.98 (s, 1H), 7.89-7.82 (m, 2H), 7.44-7.37 (m, 2H), 7.16 (t, J = 8.0 Hz, 1H), 6.99 (dd, J = 8.3, 1.1 Hz, 1H), 6.90 (dd, J = 7.7, 1.1 Hz, 1H), 3.84 (s, 3H), 2.03 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 193.87, 168.20, 151.78, 138.94, 135.41, 133.54, 131.76, 128.38, 124.91, 123.78, 120.92, 112.84, 55.93, 23.58.

***N*-(2-(4-Chlorobenzoyl)-6-methoxyphenyl)acetamide (Table 3, product 3fl)^[12]**




Hexane: EtOAc = 1:3, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 8.73 (s, 1H), 7.71 (d, J = 8.5 Hz, 2H), 7.32 (d, J = 8.5 Hz, 2H), 7.24-7.20 (m, 1H), 7.06 (d, J = 5.0 Hz, 2H), 2.12 (s, 3H), 1.85 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 196.39, 168.96, 139.61, 135.52, 135.39, 134.02, 133.89, 131.94, 128.58, 127.34, 125.30, 77.46, 77.14, 76.82, 23.18, 18.47.

***N*-(2-(4-Chlorobenzoyl)-5-methylphenyl)acetamide (Table 3, product 3gl)^[12]**




Hexane: EtOAc = 1:2, R_f = 0.3; ^1H NMR (400 MHz, CDCl_3) δ 10.90 (s, 1H), 8.49 (s, 1H), 7.64-7.58 (m, 2H), 7.51-7.43 (m, 2H), 7.40 (d, J = 8.1 Hz, 1H), 6.89 (dd, J = 8.0, 0.8 Hz, 1H), 2.43 (s, 3H), 2.23 (s, 3H); ^{13}C NMR (101 MHz, d-DMSO) δ 194.06, 168.08, 142.33, 137.12, 136.27, 131.21, 131.10, 130.12, 128.71, 128.19, 124.67, 123.50, 23.13, 21.04.

***N*-(2-(4-Chlorobenzoyl)-4-methylphenyl)acetamide (3hl)¹²**




Hexane: EtOAc = 1:3, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.74 (s, 1H), 8.61 (d, J = 8.4 Hz, 1H), 7.63 (d, J = 8.1 Hz, 2H), 7.57 (t, J = 7.6 Hz, 2H), 7.31 (s, 1H), 7.09 (t, J = 7.6 Hz, 1H), 2.46 (s, 3H), 2.23 (s, 3H); ^{13}C NMR (101 MHz, d-DMSO) δ 199.36, 169.22, 143.53, 140.19, 135.82, 133.97, 133.29, 130.23, 129.04, 123.68, 122.05, 121.58, 25.27, 21.67.

***N*-(2-(4-Chlorobenzoyl)-5-methoxyphenyl)acetamide (Table 3, product 3il)^[12]**




Hexane: EtOAc = 1:3, R_f = 0.3; ^1H NMR (400 MHz, CDCl_3) δ 11.48 (s, 1H), 8.40 (d, J = 2.6 Hz, 1H), 7.62-7.56 (m, 2H), 7.51-7.44 (m, 3H), 6.59 (dd, J = 8.9, 2.6 Hz, 1H), 3.92 (s, 3H), 2.27 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 197.62, 169.66, 164.84, 143.91, 138.10, 137.75, 135.93, 130.78, 128.59, 115.21, 109.11, 104.88, 55.71, 25.57.

***N*-(2-(4-Chlorobenzoyl)-4-methoxyphenyl)acetamide (Table 3, product 3jl)^[12]**




Hexane: EtOAc = 1:3, R_f = 0.3; ^1H NMR (400 MHz, CDCl_3) δ 10.20 (s, 1H), 8.46 (d, J = 9.1 Hz, 1H), 7.70 (d, J = 8.5 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.15 (dd, J = 9.1, 3.0 Hz, 1H), 6.99 (d, J = 3.0 Hz, 1H), 3.77 (s, 3H), 2.20 (s, 3H); ^{13}C NMR (101 MHz, d-DMSO) δ 193.21, 167.89, 155.79, 137.38, 135.64, 132.73, 131.27, 131.10, 128.22, 125.77, 117.13, 113.84, 55.42, 22.57.

***N*-(2-(4-Chlorobenzoyl)naphthalen-1-yl)acetamide (Table 3, product 3kl)^[12]**




Hexane: EtOAc = 1:3, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 8.91 (s, 1H), 7.95 (dd, J = 17.6, 8.3 Hz, 2H), 7.80 (d, J = 8.3 Hz, 3H), 7.59 (dd, J = 18.0, 6.1 Hz, 2H), 7.53 (s, 2H), 7.46-7.42 (m, 2H), 2.19 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 196.86, 169.80, 139.72, 135.35, 134.84, 131.92, 131.36, 130.38, 128.83, 128.65, 128.07, 127.77, 126.88, 125.70, 124.88, 124.18, 23.54.

(2-Aminopyridin-3-yl)(4-chlorophenyl)methanone (Table 3, product 3ll)^[12]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 9.07 (s, 1H), 8.38 (d, J = 8.4 Hz, 1H), 8.19 (s, 1H), 7.91-7.84 (m, 2H), 7.81-7.70 (m, 1H), 7.45 (d, J = 8.6 Hz, 2H), 7.06 (dd, J = 6.9, 5.3 Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 164.84, 151.49, 147.82, 138.58, 132.71, 129.07, 128.75, 120.09, 114.38.

Methyl 4-acetamido-3-(4-chlorobenzoyl)benzoate (Table 3, product 3ml)^[12]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.86 (s, 1H), 8.69 (d, J = 9.4 Hz, 2H), 8.17 – 8.12 (m, 3H), 7.59 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 8.5 Hz, 2H), 3.81 (s, 2H), 2.19 (s, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 196.86, 168.40, 143.23, 138.54, 135.35, 134.41, 133.70, 130.31, 127.95, 127.65, 122.67, 121.09, 120.00, 51.30, 24.40.

Ethyl 4-acetamido-3-(4-chlorobenzoyl)benzoate (Table 3, product 3nl)^[12]




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 10.93 (s, 1H), 8.76 (d, J = 9.4 Hz, 1H), 8.23 (s, 2H), 7.67 (d, J = 8.5 Hz, 2H), 7.51 (d, J = 8.5 Hz, 2H), 7.38 (s, 1H), 4.36 (d, J = 7.1 Hz, 2H), 2.27 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H); ^{13}C NMR (101 MHz, CDCl_3) δ 196.85, 168.36, 143.13, 138.52, 135.36, 134.31, 133.69, 130.32, 127.91, 127.53, 123.05, 121.10, 119.93, 60.26, 24.38, 13.28.

***N*-(2-(4-Chlorobenzoyl)phenyl)benzamide (Scheme 2, product 5)^[11]**




Hexane: EtOAc = 1:5, R_f = 0.4; ^1H NMR (400 MHz, CDCl_3) δ 11.83 (s, 1H), 8.68 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 2H), 7.57-7.52 (m, 5H), 7.46 (d, J = 7.4 Hz, 1H), 7.36 (dd, J = 7.6, 1.2 Hz, 1H), 7.30 (d, J = 4.4 Hz, 1H), 7.26 (d, J = 7.3 Hz, 1H); ^{13}C NMR (101 MHz, CDCl_3) δ 198.97, 190.95, 141.06, 138.99, 137.00, 134.87, 134.49, 133.70, 132.16, 130.92, 129.47, 128.88, 127.40, 122.86, 122.31, 121.64.

***N*-(2-(4-Chlorobenzoyl)phenyl)isobutyramide (Scheme 2, product 6)^[12]**




Hexane: EtOAc = 1:10, R_f = 0.3; ^1H NMR (400 MHz, CDCl_3) δ 10.87 (s, 1H), 8.69 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.5 Hz, 2H), 7.58 (s, 1H), 7.55-7.53 (m, 1H), 7.47 (d, J = 8.5 Hz, 2H), 7.08 (s, 1H), 1.30 (s, 3H), 1.28 (s, 2H); ^{13}C NMR (101 MHz, CDCl_3) δ 198.54, 176.56, 140.93, 138.94, 137.03, 134.63, 133.39, 131.40, 128.99, 128.92, 121.98, 121.64, 37.09, 19.50.


***N*-(2-(4-Chlorobenzoyl)phenyl)pivalamide (Scheme 2, product 7)^[12]**





Hexane: EtOAc = 1:10, R_f = 0.3; NMR (400 MHz, CDCl_3) δ 11.12 (s, 1H), 8.73 (s, 1H), 8.71 (d, J = 8.5 Hz, 2H), 7.65 (d, J = 8.5 Hz, 1H), 7.60-7.56 (m, 2H), 7.48 (s, 1H), 7.10 – 7.07 (m, 1H), 1.35 (s, 9H); ^{13}C NMR (101 MHz, CDCl_3) δ 198.50, 177.74, 141.19, 138.84, 137.09, 134.65, 133.51, 131.29, 128.90, 128.65, 121.92, 121.55, 40.18, 27.79.


5. ^1H and ^{13}C NMR and HRMS spectra


































#















































































































































6. References

-
- [1] W. L. F. Armarego and D. D. Perrin, *In Purification of Laboratory Chemicals*, 4th Ed., Butterworth-Heinemann: Oxford UK: 1996.
- [2] D. M. Tschaen, L. Abramson, D. Cai, R. Desmond, U.-H. Dolling, L. Frey, S. Karady, Y. Shi and T. R. Verhoeven, *J. Org. Chem.* 1995, **60**, 4322.
- [3] L. Huang, Z. Luo, F. He, J. Lu and X. Li, *Bioorg. Med. Chem.* 2010, **18**, 4475.
- [4] P. Fang, M. Z. Li and H. Ge, *J. Am. Chem. Soc.* 2010, **132**, 11898.
- [5] K. K. Park and J. J. Lee, *Tetrahedron* 2004, **60**, 2993.
- [6] J. H. Adams, P. Gupta, M. S. Khan and J. R. Lewis, *J. Chem. Soc. Perkin Transactions 1: Organic and Bio-Organic Chemistry* 1977, **19**, 2173.
- [7] M. C. Carter, D. G. Alber, R. C. Baxter, S. K. Bithell, J. Budworth, A. Chubb, G. S. Cockerill, V. C. L. Dowdell, E. A. Henderson, S. J. Keegan, R. D. Kelsey, M. J. Lockyer, J. N. Stables, L. J. Wilson and K. L. Powell, *J. Med. Chem.* 2006, **49**, 2311.
- [8] K. G. Deshpande, K. S. Naragund and S. N. Kulkarni, *J. Indian Chem. Soc.* 1978, **55**, 813.
- [9] D. Lednicer and D. E. Emmert, *J. Heterocycl. Chem.* 1971, **8**, 903.
- [10] P. R. Angibaud, M. G. Venet, W. Filliers, R. Broeckx, Y. A. Ligny, P. Muller, V. S. Poncelet and D. W. End, *Eur. J. Org. Chem.* 2004, **3**, 479.
- [11] W. Zahler and R. Huisgen, *Chem. Ber.* 1963, **96**, 765.
- [12] Y. Wu, B. Li, F. Mao, X. Li and F. Y. Kwong, *Org. Lett.* 2011, **13**, 3258.